BALCAO · SERVICES-TESTING LABORATORIES · SMALL CAP
Hypha Labs, Inc. FUNI
15 fiscal years on record · USD · FY2025 reported · SEC filings only
$-3.1M
$-412,941
Growth
—
Revenue, FY2025 · full 15-year series below
Revenue $M
Net income $M
FY2022 · Revenue 2.7 · Net income -2.1
Compound annual growth
Revenue compounded at +7.3% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2022 · Operating -42.6% · Net -76.2%
ROE
FY2019 · ROE -250.7%
The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | · | 0.0 | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| EPS, diluted $ | −0.02 | −0.01 | 0.00 | −0.03 | −0.01 | −0.04 | −0.04 | −0.04 | −0.04 | −0.20 | −0.37 | 2447106.00 | −0.06 | −0.06 | −0.01 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | −250.7 | −136.6 | −80.6 | −205.8 | −105.8 | −107.2 | · | · | −136.9 |
| Shares out B | 0.15 | 0.12 | 0.09 | 0.08 | 0.07 | 0.06 | 0.05 | 0.04 | 0.04 | 0.02 | 0.01 | 0.01 | 0.01 | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 2 failures in 70 reconciliationsAUDITED
Reconciled in 13 of 19 fiscal years. 25 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityServices-Testing Laboratories
Listed onOTC market
Incorporated inNevada
Fiscal year endsSeptember 30
SEC categorysmaller reporting company
Data on record since2011